Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial
In this RCT (n=400), imatinib (800mg load followed by 400mg daily on days 1-9) did not reduce the time to discontinuation of ventilation and supplemental oxygen for more than 48 consecutive hours in patients with COVID-19 requiring supplemental oxygen.
Source:
The Lancet Respiratory Medicine
SPS commentary:
The authors note that a benefit for imatinib was observed for one of the secondary endpoints - median duration of invasive mechanical ventilation (7 days versus 12 days placebo; p=0.0080) - but that further studies are required to validate these findings.